Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 28.15 USD 0.04% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Immunocore Holdings PLC?
Write Note

Immunocore Holdings PLC
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Immunocore Holdings PLC
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Immunocore Holdings PLC
NASDAQ:IMCR
Accrued Liabilities
ÂŁ121.2m
CAGR 3-Years
85%
CAGR 5-Years
58%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Accrued Liabilities
$27.5m
CAGR 3-Years
202%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Accrued Liabilities
ÂŁ22.2m
CAGR 3-Years
123%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Accrued Liabilities
$44.6m
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Accrued Liabilities
$38.7m
CAGR 3-Years
54%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Immunocore Holdings PLC
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

Immunocore Holdings PLC stands as a pioneering force in the field of immunotherapy, leveraging its proprietary T-cell receptor (TCR) technology to transform the treatment landscape for various severe diseases. Rooted in cutting-edge science, the British biotech firm develops novel therapeutic agents targeting cancer, infectious diseases, and autoimmune conditions. Its leading platform technology, known as ImmTACs (Immune Mobilizing Monoclonal TCRs Against Cancer), ingeniously redirects T-cells—an integral component of the immune system—to recognize and obliterate cancerous cells in a highly targeted manner. By focusing on ultra-specific peptide-major histocompatibility complex (pMHC) targets, Immunocore meticulously designs its therapies to minimize off-target effects and maximize efficacy in tackling conditions that have eluded traditional treatment methods. Financially, Immunocore operates through a strategic blend of commercial and collaborative partnerships, alongside its independent pipeline advancements. It generates revenue by licensing its innovative technology to larger pharmaceutical entities that seek to add cutting-edge biologics to their portfolios. Additionally, milestone and royalty payments from collaborative research initiatives contribute significantly to its financial foundation. These partnerships not only bolster Immunocore's revenue streams but also accelerate its research and development efforts, enabling a faster path to market for its groundbreaking treatments. As a result, the company stands at the confluence of science and commerce, channeling its unique TCR technology to make meaningful strides in medical innovation and patient care.

IMCR Intrinsic Value
113.11 USD
Undervaluation 75%
Intrinsic Value
Price

See Also

What is Immunocore Holdings PLC's Accrued Liabilities?
Accrued Liabilities
121.2m GBP

Based on the financial report for Dec 31, 2023, Immunocore Holdings PLC's Accrued Liabilities amounts to 121.2m GBP.

What is Immunocore Holdings PLC's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
58%

Over the last year, the Accrued Liabilities growth was 94%. The average annual Accrued Liabilities growth rates for Immunocore Holdings PLC have been 85% over the past three years , 58% over the past five years .

Back to Top